Related Experiment Video
Updated: Feb 12, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With
E I Tashina1, E V Privalova1, V Yu Kaplunova1
1Sechenov First Moscow State Medical University, Moscow.
Aim:
To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group).
Material And Methods:
A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction.
Results:
Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 vs. 2.03; p<0.001) and significant decreases in microRNA-29a (0.24 vs. 1.83; p<0.001) and microRNA-133a (0.02 vs. 6.34; p<0.001). ROC analysis demonstrated a high discriminatory ability of the studied microRNAs: microRNA-21 (AUC=0.887, sensitivity 89.7%, specificity 84.4%); microRNA-29a (AUC=0.884, sensitivity 92.3%, specificity 87.5%).
Conclusion:
Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.
Insights
A panel of microRNAs (miRNAs) can help diagnose hypertrophic cardiomyopathy (HCM). Specific miRNA levels, including increased microRNA-21 and decreased microRNA-29a, show diagnostic potential for HCM.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Biomarker Discovery
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary genetic heart disease.
- Accurate diagnosis and risk stratification are crucial for managing HCM.
- Novel diagnostic markers are needed to improve early detection and patient outcomes.
Purpose of the Study:
- To investigate the diagnostic value of circulating microRNA panel (-21, -29a, -133a) in patients with HCM.
- To compare microRNA expression levels between HCM patients and a control group with arterial hypertension.
- To assess the potential of these microRNAs as auxiliary diagnostic markers for HCM.
Main Methods:
- A comparative study included 40 patients with confirmed HCM and 40 age- and sex-matched controls.
- Comprehensive cardiac assessments included ECG, echocardiography, and Holter monitoring.
- Plasma levels of microRNAs -21, -29a, and -133a were quantified using real-time PCR.
Main Results:
- Significant differences in microRNA expression were observed between HCM patients and controls.
- MicroRNA-21 was significantly increased (p<0.001), while microRNA-29a (p<0.001) and microRNA-133a (p<0.001) were significantly decreased in HCM patients.
- Receiver Operating Characteristic (ROC) analysis showed high diagnostic accuracy for microRNA-21 (AUC=0.887) and microRNA-29a (AUC=0.884).
Conclusions:
- The microRNA panel (-21, -29a, -133a) demonstrates significant diagnostic potential for HCM.
- Elevated microRNA-21 and reduced microRNA-29a correlate with myocardial fibrosis.
- Suppressed microRNA-133a indicates hypertrophic remodeling, suggesting these miRNAs as promising auxiliary markers for HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
MicroRNAs
MicroRNAs
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Wood Panel Products

